Amrutanjan Health Care share price & results
- Jun 2026
- Sept 2026
Chennai FMCG maker of Amrutanjan pain balms, Relief congestion rubs, Comfy napkins and Electro+ rehydration drinks/ORS since 1893.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 103 | +9.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 6.1 | −2.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 4.4 | −47.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | +4.1 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. | |
| Free cash flow margin | +3.4 pts | Fiscal year | FY · period unavailable | Not in the analysed materials. No older figure is substituted. | |
| Revenue growth (YoY) | −5.9 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. |
Price
Performance −31.7% 1Y
1Y: ₹717.2 on 24 Oct 2025 → ₹489.5. High ₹741.5 (29 Oct 2025), low ₹487.65 (23 Oct 2026).
- Previous close
- ₹489.75
- Market cap
- ₹1.4k Cr
- 52-week range
- ₹487.65 – ₹741.5
- One year
- −32.02%
Overview
- Symbol
- NSE:AMRUTANJAN
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Amrutanjan Health Care Limited does
Based on the company's own presentations, annual report and earnings calls.
Amrutanjan Health Care manufactures and markets over-the-counter pain-relief and congestion products, women's hygiene and personal-care items, and rehydration/ORS beverages, distributed nationally through a stockist-distributor network into chemists, general trade and modern trade. Its OTC portfolio (Amrutanjan balms, roll-ons, sprays and patches for pain, and the Relief brand for congestion) is produced at plants in Alathur, Kancheepuram district, Tamil Nadu and Uppal, Hyderabad, Telangana. The Comfy brand of sanitary napkins, along with newly added personal-care lines such as razors and antiseptic plaster, and the Electro+/Enerlyte rehydration drinks and WHO-approved ORS powders (made at a dedicated beverage plant in Aranvoyal village, Tiruvallur district, Tamil Nadu) round out the portfolio. The company also runs an in-house QA/R&D function supporting formulation and product development.
Segments
- OTC Products
- Women's Hygiene & Personal Care
- Beverages
- Manufacturing units
- 3 (Alathur, Tamil Nadu; Uppal, Telangana - OTC; Aranvoyal, Tamil Nadu - Beverages)
- Distributors
- 1,656
- Outlet reach (Rubefacient segment)
- 1.11 Mn outlets
- Employees
- 631
- Suppliers
- 914
- Core power brands
- 4 (Amrutanjan, Relief, Comfy, Enerlyte/Electro+)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2011 to Mar 2016).
Financials
What the filings say
Net profit, year on year: −47% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 110 | 123 | 135 | 94 | 118 | 141 | 150 | 103 |
| Expenses | 96 | 99 | 118 | 86 | 101 | 116 | 124 | 97 |
| Operating profit | 14 | 23 | 18 | 8 | 17 | 25 | 26 | 6 |
| Operating margin | 12.4% | 19.0% | 13.1% | 9.0% | 14.0% | 17.9% | 17.1% | 6.1% |
| Other income | 4 | 4 | 5 | 4 | 4 | 3 | -3 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 16 | 26 | 21 | 11 | 19 | 26 | 21 | 6 |
| Tax rate | 26.0% | 25.9% | 27.2% | 26.4% | 27.3% | 26.2% | 22.9% | 28.1% |
| Net profit | 12 | 19 | 15 | 8 | 14 | 19 | 16 | 4 |
| EPS (₹ per share) | 4.08 | 6.66 | 5.25 | 2.87 | 4.83 | 6.73 | 5.60 | 1.51 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 380 | 421 | 452 | 503 |
| Expenses | 335 | 369 | 394 | 427 |
| Operating profit | 44 | 52 | 58 | 76 |
| Other income | 15 | 16 | 18 | 9 |
| Interest | 0 | 0 | 0 | 0 |
| Depreciation | 5 | 6 | 7 | 6 |
| Profit before tax | 53 | 62 | 69 | 78 |
| Net profit | 41 | 45 | 51 | 58 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 262 | 288 | 286 | 324 | 339 | 367 |
| Borrowings | 1 | 1 | 2 | 2 | 2 | 2 |
| Other liabilities | 84 | 70 | 77 | 93 | 88 | 137 |
| Total liabilities | 350 | 362 | 367 | 421 | 432 | 509 |
| Fixed assets | 28 | 49 | 50 | 49 | 49 | 51 |
| Capital work in progress | 17 | 1 | 2 | 16 | 26 | 106 |
| Investments | 13 | 5 | 0 | 0 | 0 | 3 |
| Other assets | 291 | 307 | 315 | 356 | 357 | 349 |
| Total assets | 350 | 362 | 367 | 421 | 432 | 509 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 91 | 52 | 20 | 28 | 51 | 36 |
| Cash from investing | -88 | -36 | -2 | 19 | -31 | -21 |
| Cash from financing | -7 | -17 | -15 | -48 | -13 | -14 |
| Net cash flow | -4 | -1 | 3 | -1 | 6 | 1 |
| Free cash flow | 89 | 29 | 11 | 21 | 15 | -19 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 19 | 34 | 32 | 42 | 45 | 44 |
| Inventory days | 45 | 53 | 58 | 50 | 45 | 56 |
| Days payable | 106 | 122 | 95 | 96 | 113 | 106 |
| Cash conversion cycle | -41 | -35 | -6 | -5 | -23 | -6 |
| Working capital days | 28 | 92 | 117 | 173 | 99 | 94 |
| Return on capital employed | 44.0% | 38.0% | 19.0% | 21.0% | 22.0% | 25.0% |
| Dividend payout | 20.0% | 20.0% | 34.0% | 30.0% | 26.0% | 24.0% |
Where revenue comes from
The businesses behind the company’s reported revenue.
OTC Products contributes 55.6% of reported segment revenue.
Quarter ended 30 Jun 2026 · Standalone
- OTC Products 55.6%
₹57.26 crore
- Women's Hygiene & Personal Care 35.3%
₹36.36 crore
- Beverages 8.4%
₹8.64 crore
- Others 0.7%
₹0.72 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| OTC Products | 57.26 | 55.6% |
| Women's Hygiene & Personal Care | 36.36 | 35.3% |
| Beverages | 8.64 | 8.4% |
| Others | 0.72 | 0.7% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
How these numbers add up
- Total segment revenue
- ₹102.97 crore
- Intersegment adjustment
- ₹0.00 crore
- Net segment revenue
- ₹102.97 crore
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
What the price assumes
ExpensiveTo justify its price of ₹490, this stock must grow earnings at 19% every year for 7 years. Our analysis caps realistic growth at ~14%. At that growth it is worth ₹372 — downside of 24%.
- Growth the price implies
- 19.0% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 12.5% a year
- net profit, FY23–FY26 · EPS 13.7%
- The gap
- 0.1 pp
- -24% downside if it only repeats history
Ownership
Who owns it
Promoters hold 46.52% as of Sept 2026; institutions cut 4.36 pts since Jun 2026.
- Promoters 46.52%
- Foreign institutions 3.47%
- Domestic institutions 6.90%
- Public 43.08%
- Others 0.04%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 4.74% held
- newly disclosed 3.47% held
- newly disclosed 2.31% held
- FPI fund newly disclosed 2.02% held
The same filing shows 0 holders trimming and 5 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Amrutanjan Health Care Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 20.15% | unchanged | |
| 10.34% | unchanged | |
| 4.74% | newly disclosed | |
| 3.47% | newly disclosed | |
| 3.02% | unchanged | |
| 2.53% | unchanged | |
| 2.31% | newly disclosed | |
| 2.13% | unchanged | |
| FPI fund | 2.02% | newly disclosed |
| 1.50% | unchanged | |
| 1.16% | unchanged | |
| — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Amrutanjan Health Care Limited
Free account: one company. Everything above stays public.
Write why you follow Amrutanjan Health Care Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Amrutanjan Health Care Limited
Guides on how to read this kind of business and the numbers that matter.